echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > Two blood molecules "track" the progress of Alzheimer's disease

    Two blood molecules "track" the progress of Alzheimer's disease

    • Last Update: 2020-12-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Nov. 30 (Xinhua Zhang Mengran) According to a medical study published in the British journal Nature Aging on the 30th, a team of European scientists found for the first time that levels of two molecules in the blood may be able to predict mild cognitive impairment: future cognitive decline in patients and the development of Alzheimer's disease. The two molecules are phosphatized tau (P-tau181) and nerve wire light chain (NfL) on suline-181 bits, respectively. The results could help scientists develop routine blood tests to "track" the progress of Alzheimer's disease in high-risk groups.
    the present, humans are still helpless on Alzheimer's disease, an important reason is the cause of the disease "absence", making it difficult to prevent and "track." Such an unexplained and incurable disease is not uncommon - data show that there are about 50 million people with Alzheimer's worldwide, accounting for 50 to 70 per cent of all dementia cases. Alzheimer's disease is characterized by proteins thought to cause neuron death to aggregate in the brain and eventually develop dementia. New research has found that these proteins are also present in the blood - so testing their concentration in plasma can diagnose the disease or distinguish it from other common forms of dementia.
    , scientist Oscar Hansen of Lund University in Sweden and colleagues used data from 573 patients with mild cognitive impairment to build and validate individualized risk models. Through this model, patients' cognitive decline and the development of Alzheimer's disease can be predicted.
    team compared multiple models to predict the accuracy of cognitive decline and dementia progression over a four-year span, based on a variety of combinations of different biomarkers in the blood. They found that models based on P-tau181, a form of tau protein, and NfL, which reflect neuron death and injury, were the best predictive.
    researchers concluded that their findings prove that predicting the progression of alzheimer's disease in individuals with biomarkers in the blood is valuable, and that larger queue studies are needed next.
    scientists believe that pathologically, Alzheimer's patients are primarily neurons and synapses in the brain and specific lower cortical regions, which can lead to significant brain atrophy and decline. Although the exact cause is not yet clear, the scientific community has invested heavily in studying the pathogenesis of Alzheimer's disease and exploring treatment options, and in addition to pathological research approaching
    , the advent of some drugs has also brought hope to patients in prevention and treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.